ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM
Abstract Number: 2204
Distinctive Personality Profiles of Fibromyalgia and Chronic Fatigue Syndrome Patients
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus
9:00AM-11:00AM
Abstract Number: 2496
DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center
Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events
9:00AM-11:00AM
Abstract Number: 2108
DNA Hypomethylation in Promoter Region of Zbtb38 Gene Ultimately Leads to Downregulated Expression of Anti-Inflammatory IL1r2 in Experiential Model of Rheumatoid Arthritis
B Cell Biology and Targets in Autoimmune Disease - Poster II: Rheumatoid Arthritis and Other Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 2450
Do Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Have Reduced Fertility and Parity? a Systematic Review
Reproductive Issues in Rheumatic Disorders - Poster
9:00AM-11:00AM
Abstract Number: 2218
Do Some Patients with Distal Upper Limb Pain Benefit More Than Others from Advice to Remain Active?
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus
9:00AM-11:00AM
Abstract Number: 2743
Do Specific Entheseal Points in Spa Patients Impact Patient Reported Outcomes? Implications for Clinical Practice
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III
9:00AM-11:00AM
Abstract Number: 2660
Do Ultrasonographic Lesions of Salivary Glands Evolve in SjöGren Patients during Follow-up ?
Sjögren's Syndrome - Poster II: Clinical Science
9:00AM-11:00AM
Abstract Number: 2736
Do Validated Tools of Disease Activity in Ankylosing Spondylitis Measure Fibromyalgia Pain?
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III
9:00AM-11:00AM
Abstract Number: 2447
Does a History of Abnormal Pap Smear or Preceeding HPV Infection Affect Humoral Immune Response to Quadrivalent Human Papilloma Virus (qHPV) Vaccine in Women with Systemic Lupus Erythematosus (SLE)
Reproductive Issues in Rheumatic Disorders - Poster
9:00AM-11:00AM
Abstract Number: 2348
Does Arthritis in Other Joints and Spine Influence the 1-Year Outcome of Total Hip Replacement? a Prospective European Multicenter Cohort Study  Measuring the Influence of Musculoskeletal Morbidity
Osteoarthritis – Clinical Aspects - Poster II
9:00AM-11:00AM
Abstract Number: 2514
Does Combination of Conventional Synthetic Disease Modifying Antirheumatic Drug with Anti-TNF Influence the Long Term Retention Compared to Anti-TNF Monotherapy in Psoriatic Arthritis? an Analysis from Rhumadata® over 12 Years
Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events
9:00AM-11:00AM
Abstract Number: 2769
Does Gender Make a Difference in “Composite Psoriatic Disease Activity Index (CPDAI)” in Patients with Psoriatic Arthritis?
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III
9:00AM-11:00AM
Abstract Number: 2339
Does Physical Activity Change after Total Hip or Knee Arthroplasty: A Systematic Review and Meta-Analysis
Orthopedics, Low Back Pain and Rehabilitation - ARHP Poster
9:00AM-11:00AM
Abstract Number: 2716
Does Secretory Immunoglobulin a Influence Disease Activity in Patients with Reactive Arthritis and Undifferentiated Spondylarthritis?
Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II
9:00AM-11:00AM
Abstract Number: 2359
Dose-Related Risks of Cardiovascular, Gastrointestinal, and Renal Adverse Events Associated with Meloxicam Among Patients with Osteoarthritis: An Observational Study Using US Claims Data
Osteoarthritis – Clinical Aspects - Poster II
  • «Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 69
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology